# Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

> **NCT04345913** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Copanlisib Hydrochloride
- **DRUG:** Eribulin Mesylate
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT04345913
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2024-03-28
- **Final completion:** 2026-05-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345913, "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04345913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*